-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2023-505311-20-00
5
Metastatic Non-Small Cell Lung Cancer
-
2024-512195-35-00
5
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2023-503221-19-00
4
2024-04-18
Advanced Non-Small Cell Lung Cancer
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-517432-21-00
4
2025-05-30
Gynecological Cancers
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-516173-76-01
5
2025-04-22
HER2-positive or HER2-low (incl. ultra-low) early breast cancer
-
2022-500574-34-00
4
2025-03-21
Waldenström’s Macroglobulinemia
-
2023-505311-20-01
5
2025-03-21
Metastatic Non-Small Cell Lung Cancer
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2024-516504-42-00
5
2022-03-05
Respiratory distress syndrome in preterm infants
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2022-500571-32-00
4
2024-05-15
Early-Stage Unfavorable Classical Hodgkin Lymphoma
-
2024-512980-29-00
4
2023-08-28
T1-T2N0 esophageal adenocarcinoma including gastroesophageal
junction